Global Pulmonary Arterial Hypertension (PAH) Drugs Market Research Report 2021

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Research Report 2021

Table of Contents
1 Pulmonary Arterial Hypertension (PAH) Drugs Market Overview
1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Drugs
1.2 Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Inhalation
1.2.3 Injectables
1.2.4 Oral Administration
1.3 Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application
1.3.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue 2016-2027
1.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2016-2027
1.4.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Pulmonary Arterial Hypertension (PAH) Drugs Market Competition by Manufacturers
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Pulmonary Arterial Hypertension (PAH) Drugs Market Competitive Situation and Trends
2.5.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Pulmonary Arterial Hypertension (PAH) Drugs Players Market Share by Revenue
2.5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario by Region
3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
3.3.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
3.3.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
3.4.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
3.4.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region
3.5.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
3.6.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
3.6.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
3.7.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Analysis by Type
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2016-2021)
4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2016-2021)
5 Global Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Analysis by Application
5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2016-2021)
5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Glaxosmithkline
6.2.1 Glaxosmithkline Corporation Information
6.2.2 Glaxosmithkline Description and Business Overview
6.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Glaxosmithkline Product Portfolio
6.2.5 Glaxosmithkline Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Novartis Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 United Therapeutics
6.4.1 United Therapeutics Corporation Information
6.4.2 United Therapeutics Description and Business Overview
6.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 United Therapeutics Product Portfolio
6.4.5 United Therapeutics Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 AstraZeneca Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Merck Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 Bayer Healthcare
6.6.1 Bayer Healthcare Corporation Information
6.6.2 Bayer Healthcare Description and Business Overview
6.6.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bayer Healthcare Product Portfolio
6.7.5 Bayer Healthcare Recent Developments/Updates
6.8 Actelion Pharmaceuticals
6.8.1 Actelion Pharmaceuticals Corporation Information
6.8.2 Actelion Pharmaceuticals Description and Business Overview
6.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Actelion Pharmaceuticals Product Portfolio
6.8.5 Actelion Pharmaceuticals Recent Developments/Updates
6.9 Daiichi Sankyo
6.9.1 Daiichi Sankyo Corporation Information
6.9.2 Daiichi Sankyo Description and Business Overview
6.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Daiichi Sankyo Product Portfolio
6.9.5 Daiichi Sankyo Recent Developments/Updates
6.10 Northern Therapeutics
6.10.1 Northern Therapeutics Corporation Information
6.10.2 Northern Therapeutics Description and Business Overview
6.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Northern Therapeutics Product Portfolio
6.10.5 Northern Therapeutics Recent Developments/Updates
6.11 Aires Pharmaceuticals
6.11.1 Aires Pharmaceuticals Corporation Information
6.11.2 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Description and Business Overview
6.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Aires Pharmaceuticals Product Portfolio
6.11.5 Aires Pharmaceuticals Recent Developments/Updates
6.12 Arena Pharmaceuticals
6.12.1 Arena Pharmaceuticals Corporation Information
6.12.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Description and Business Overview
6.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Arena Pharmaceuticals Product Portfolio
6.12.5 Arena Pharmaceuticals Recent Developments/Updates
6.13 Berlin Cures
6.13.1 Berlin Cures Corporation Information
6.13.2 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Description and Business Overview
6.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Berlin Cures Product Portfolio
6.13.5 Berlin Cures Recent Developments/Updates
6.14 Eiger BioPharmaceuticals
6.14.1 Eiger BioPharmaceuticals Corporation Information
6.14.2 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Description and Business Overview
6.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Eiger BioPharmaceuticals Product Portfolio
6.14.5 Eiger BioPharmaceuticals Recent Developments/Updates
6.15 Reata Pharmaceuticals
6.15.1 Reata Pharmaceuticals Corporation Information
6.15.2 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Description and Business Overview
6.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Reata Pharmaceuticals Product Portfolio
6.15.5 Reata Pharmaceuticals Recent Developments/Updates
7 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Cost Analysis
7.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs
7.4 Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
8.3 Pulmonary Arterial Hypertension (PAH) Drugs Customers
9 Pulmonary Arterial Hypertension (PAH) Drugs Market Dynamics
9.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends
9.2 Pulmonary Arterial Hypertension (PAH) Drugs Growth Drivers
9.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
9.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
10 Global Market Forecast
10.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Drugs by Type (2022-2027)
10.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Drugs by Application (2022-2027)
10.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) Comparison by Application (2021-2027)
Table 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Covered in This Study
Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) of Key Manufacturers (2016-2021)
Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Manufacturers (2016-2021)
Table 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Pulmonary Arterial Hypertension (PAH) Drugs Average Price (USD/Pcs) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2016-2021) & (K Pcs)
Table 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2016-2021) & (K Pcs)
Table 19. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2016-2021) & (K Pcs)
Table 23. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2016-2021) & (K Pcs)
Table 27. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2016-2021) & (K Pcs)
Table 31. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2016-2021) & (K Pcs)
Table 35. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2016-2021)
Table 39. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2016-2021)
Table 42. Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs) by Type (2016-2021)
Table 43. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2016-2021)
Table 44. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2016-2021)
Table 47. Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs) by Application (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 51. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 52. Pfizer Recent Developments/Updates
Table 53. Glaxosmithkline Corporation Information
Table 54. Glaxosmithkline Description and Business Overview
Table 55. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 56. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 57. Glaxosmithkline Recent Developments/Updates
Table 58. Novartis Corporation Information
Table 59. Novartis Description and Business Overview
Table 60. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 61. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 62. Novartis Recent Developments/Updates
Table 63. United Therapeutics Corporation Information
Table 64. United Therapeutics Description and Business Overview
Table 65. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 66. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 67. United Therapeutics Recent Developments/Updates
Table 68. AstraZeneca Corporation Information
Table 69. AstraZeneca Description and Business Overview
Table 70. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 71. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 72. AstraZeneca Recent Developments/Updates
Table 73. Merck Corporation Information
Table 74. Merck Description and Business Overview
Table 75. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 76. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 77. Merck Recent Developments/Updates
Table 78. Bayer Healthcare Corporation Information
Table 79. Bayer Healthcare Description and Business Overview
Table 80. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 81. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 82. Bayer Healthcare Recent Developments/Updates
Table 83. Actelion Pharmaceuticals Corporation Information
Table 84. Actelion Pharmaceuticals Description and Business Overview
Table 85. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 86. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 87. Actelion Pharmaceuticals Recent Developments/Updates
Table 88. Daiichi Sankyo Corporation Information
Table 89. Daiichi Sankyo Description and Business Overview
Table 90. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 91. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 92. Daiichi Sankyo Recent Developments/Updates
Table 93. Northern Therapeutics Corporation Information
Table 94. Northern Therapeutics Description and Business Overview
Table 95. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 96. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 97. Northern Therapeutics Recent Developments/Updates
Table 98. Aires Pharmaceuticals Corporation Information
Table 99. Aires Pharmaceuticals Description and Business Overview
Table 100. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 101. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 102. Aires Pharmaceuticals Recent Developments/Updates
Table 103. Arena Pharmaceuticals Corporation Information
Table 104. Arena Pharmaceuticals Description and Business Overview
Table 105. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 106. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 107. Arena Pharmaceuticals Recent Developments/Updates
Table 108. Berlin Cures Corporation Information
Table 109. Berlin Cures Description and Business Overview
Table 110. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 111. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 112. Berlin Cures Recent Developments/Updates
Table 113. Eiger BioPharmaceuticals Corporation Information
Table 114. Eiger BioPharmaceuticals Description and Business Overview
Table 115. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 116. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 117. Eiger BioPharmaceuticals Recent Developments/Updates
Table 118. Reata Pharmaceuticals Corporation Information
Table 119. Reata Pharmaceuticals Description and Business Overview
Table 120. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 121. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 122. Reata Pharmaceuticals Recent Developments/Updates
Table 123. Production Base and Market Concentration Rate of Raw Material
Table 124. Key Suppliers of Raw Materials
Table 125. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
Table 126. Pulmonary Arterial Hypertension (PAH) Drugs Customers List
Table 127. Pulmonary Arterial Hypertension (PAH) Drugs Market Trends
Table 128. Pulmonary Arterial Hypertension (PAH) Drugs Growth Drivers
Table 129. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
Table 130. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2022-2027) & (K Pcs)
Table 131. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Type (2022-2027)
Table 132. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 133. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 134. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2022-2027) & (K Pcs)
Table 135. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Application (2022-2027)
Table 136. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 137. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 138. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Region (2022-2027) & (K Pcs)
Table 139. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Region (2022-2027)
Table 140. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 141. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Pulmonary Arterial Hypertension (PAH) Drugs
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2020 & 2027
Figure 3. Inhalation Product Picture
Figure 4. Injectables Product Picture
Figure 5. Oral Administration Product Picture
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2020 & 2027
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Other
Figure 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size 2016-2027 (US$ Million)
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2016-2027 (K Pcs)
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Manufacturers in 2020
Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest Pulmonary Arterial Hypertension (PAH) Drugs Players: Market Share by Revenue in 2020
Figure 17. Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2016-2021)
Figure 19. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region in 2020
Figure 20. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2016-2021)
Figure 21. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region in 2020
Figure 22. U.S. Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Taiwan Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Philippines Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Vietnam Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. U.A.E Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type (2016-2021)
Figure 47. Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application (2016-2021)
Figure 48. Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application in 2020
Figure 49. Revenue Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application (2016-2021)
Figure 50. Revenue Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application in 2020
Figure 51. Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Drugs
Figure 52. Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs
Figure 53. Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Pulmonary Arterial Hypertension (Pah) Medicine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 103

Market Overview of Global Pulmonary Arterial Hypertension (Pah) Medicine market: According to our latest research, the global Pulmonary Arterial Hypertension (Pah) Medicine market looks promising in the next 5 years. As of 2022, the global Pulmonary Arterial Hypertension (Pah) Medicine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to ......

Global Nifedipine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 102

Market Overview of Global Nifedipine market: According to our latest research, the global Nifedipine market looks promising in the next 5 years. As of 2022, the global Nifedipine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Nifedipine market, with a systematical de......

Global Amlodipine Besylate Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 115

The Amlodipine Besylate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amlodipine Besylate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profil......

Pulmonary Arterial Hypertension (PAH) Drugs - Global Market Insights and Sales Trends 2024

Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 112

The global Pulmonary Arterial Hypertension (PAH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other,, are propelling Pulmonary Arterial Hypertension (PAH) Drugs market. Inhalation, one of the segments analysed in this report, is projected to record % ......

Captopril API - Global Market Insights and Sales Trends 2024

Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 100

The global Captopril API market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Captopril API in various end use industries. The expanding demands from the Captopril Tablet, Compound Captopril Tablet and Captopril Injection,, are propelling Captopril API market. 98% Captopril API, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the......

Telmisartan - Global Market Insights and Sales Trends 2024

Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 107

The global Telmisartan market size is expected to reach US$ 3631.3 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Telmisartan in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Telmisartan market. Injection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-Dried......

Global Ambrisentan Professional Survey Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 106

Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......

Global Ambrisentan Market Research Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 2680 Onwards        Pages: 132

Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......

Global Amlodipine Besylate Professional Survey Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 133

Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs